Dr. Mark S. Humayun




Mark S. Humayun, MD, PhD, received his Bachelors of Science degree from Georgetown University in 1984, his Masters Doctorate from Duke University in 1989, and his PhD from the University of North Carolina, Chapel Hill in 1994. He completed his ophthalmology residency at Duke Eye Center and fellowships in both vitreoretinal and retinovascular surgery at Johns Hopkins Hospital. He stayed on as faculty at Johns Hopkins where he rose to the rank of associate professor before moving to USC in 2001.

mark-4Dr. Humayun has devoted much of his career to clinical and scientific research in ophthalmology and bioengineering, becoming both a biomedical engineer and professor of ophthalmology. Dr. Humayun led a talented and diverse team of interdisciplinary researchers with the ultimate goal of creating the world’s first artificial retina. He assembled a team of world experts with a wide range of proficiency, including biomedical engineering, computer science, medicine, chemistry, biology and business. In clinical trials since 2007 and approved by the FDA in 2013, the  , represents the culmination of a visual restoration strategy that offers an unprecedented degree of sight to those with complete retinal blindness. He was elected to the prestigious National Academy of Medicine (NAM)  and National Academy of Engineering (NAE) for his pioneering work to restore sight.

He was also featured as one of the top 10 inventors in  Time Magazine  in 2013, voted as one of the Best Doctors in America for three years, and one of the top 1% of Doctors by.

mark-pic-1In 2016, Dr. Humayun received the  National Medal of Technology and Innovation from President Barack Obama for his innovative work and development of the Argus II.

Research Interests:

As director of the USC Institute for Biomedical Therapeutics, Dr. Humayun leads a team of researchers in the investigation and development of treatments for degenerative neurological diseases using biomedical engineering technology.  Major research applications include developing the next generation of, the world Aurgus II, the mark-5world’s first FDA approved artificial retinal prosthesis for patients suffering from an inherited form of retinitis pigmentosa (RP). Dr. Humayun, in collaboration with David Hinton, MD, received a $19 million grant from the California Institute for Regenerative Medicine (CIRM) to lead a stem cell initiative.  The research team has developed a unique procedure by which a scaffold of stem-cell derived retinal pigment epithelium cells may be surgically implanted into the back of the eye, replacing diseased tissue to treat those suffering from Age-Related Macular Degeneration (AMD).

• MD, Duke University Medical School, 1989
• PhD, University of North Carolina, 1994


Play Cover Track Title
Track Authors